Replies to post #222609 on Biotech Values

[DewDiligence]

Re: RVNC-Fosun deal

Selling the rights to market RT002 in China for up to $260 million seems low to me.

RVNC’s economic interest in the Fosun deal is not $260M, but rather $260M plus royalties.

Isn’t China supposed to be the fastest growing market for Botox?

China is indeed a fast-growth market for botulinum toxin products generally, but there are several knockoff brands competing for share.

[randychub]

Seems low to me also. Looks like it also Includes all indications. The press release also looks like the expect the first approval to happen in China. Anyone have a time table/reason for that? Thank you. Randy